Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial
2024 ASCO Annual Meeting
Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We presented the first primary results of the PATRICIA cohort C trial. This is an open level, phase two randomized trial that recruited HER2-positive advanced breast cancer patients who received an experimental combination consisted on palbociclib, trastuzumab and endocrine therapy versus treatment of physician choice with T-DM1 or the combination of trastuzumab chemotherapy or endocrine treatment.
These patients were pre-treated patients, at least two prior lines of treatment, and all of them were selected based on the intrinsic subtyping. Just luminal A and luminal B tumors were included in this trial.
Primary result was achieved and progression for survival was significantly improved with combination of palbociclib trastuzumab endocrine treatment over treatment of physician's choice, with a reduction in the risk of progression of about 48%, which is statistically significant. These results are unique as we try to select patients based on a new biomarker, which is intrinsic subtype, and offering this non-chemotherapy combination for these patients that harbored about 50% within the HER-positive HER2-positive disease.
Regarding tolerability, no dose reductions were done differently from these two arms and no dose discontinuations were needed in the experimental arm. That is why our conclusions says that this is a new way to classify in patients within the HER2-positive disease. This is a non-chemo alternative for these patients that will translate, for sure, into quality of life. But still we should validate our results as our trial had some limitations due to a small sample size, so maybe new prospective randomized designs will be needed to confirm our [inaudible 00:02:21] results.
Related Videos
The ASCO Post Staff
Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).
The ASCO Post Staff
Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).
The ASCO Post Staff
Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence, including patients with node-negative disease, and showed a benefit in invasive disease–free survival (Abstract 512).
The ASCO Post Staff
Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).
The ASCO Post Staff
Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).